Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-D Baumgartner

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
New Horizons (Baltimore, Md.)|February 1, 1993
Anti-endotoxin antibodies and other inhibitors of endotoxinG Zanetti, M P Glauser, J D Baumgartner
Clinical and Experimental Immunology|July 1, 1994
Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patientsA Cometta, J D Baumgartner, M P Glauser
Progress in Clinical and Biological Research|January 1, 1991
Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shockT Calandra, J D Baumgartner, M P Glauser
Schweizerische Medizinische Wochenschrift|March 22, 1997
Sepsis and septic shockG Zanetti, J D Baumgartner, M P Glauser
Schweizerische Medizinische Wochenschrift|January 2, 2001
[Evaluation of antibiotic prophylaxis in neutropenic patients with hematologic malignancies]P Delarive, J D Baumgartner, M P Glauser, et al.
The Journal of Infectious Diseases|April 1, 1991
Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5J D Baumgartner, D Heumann, T Calandra, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 1994
Pathogenesis and potential strategies for prevention and treatment of septic shock: an updateM P Glauser, D Heumann, J D Baumgartner, et al.
The Journal of Infectious Diseases|April 1, 1991
Antibodies to core lipopolysaccharide determinants: absence of cross-reactivity with heterologous lipopolysaccharidesD Heumann, J D Baumgartner, H Jacot-Guillarmod, et al.
The American Journal of Medicine|July 1, 1991
High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study GroupT Calandra, J Gerain, D Heumann, et al.
Critical Care Medicine|July 1, 1992
A novel score for predicting the mortality of septic shock patientsJ D Baumgartner, C Büla, C Vaney, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
New Horizons (Baltimore, Md.)|February 1, 1993
Anti-endotoxin antibodies and other inhibitors of endotoxinG Zanetti, M P Glauser, J D Baumgartner
Clinical and Experimental Immunology|July 1, 1994
Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patientsA Cometta, J D Baumgartner, M P Glauser
Progress in Clinical and Biological Research|January 1, 1991
Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shockT Calandra, J D Baumgartner, M P Glauser
Schweizerische Medizinische Wochenschrift|March 22, 1997
Sepsis and septic shockG Zanetti, J D Baumgartner, M P Glauser
Schweizerische Medizinische Wochenschrift|January 2, 2001
[Evaluation of antibiotic prophylaxis in neutropenic patients with hematologic malignancies]P Delarive, J D Baumgartner, M P Glauser, et al.
The Journal of Infectious Diseases|April 1, 1991
Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5J D Baumgartner, D Heumann, T Calandra, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 1994
Pathogenesis and potential strategies for prevention and treatment of septic shock: an updateM P Glauser, D Heumann, J D Baumgartner, et al.
The Journal of Infectious Diseases|April 1, 1991
Antibodies to core lipopolysaccharide determinants: absence of cross-reactivity with heterologous lipopolysaccharidesD Heumann, J D Baumgartner, H Jacot-Guillarmod, et al.
The American Journal of Medicine|July 1, 1991
High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study GroupT Calandra, J Gerain, D Heumann, et al.
Critical Care Medicine|July 1, 1992
A novel score for predicting the mortality of septic shock patientsJ D Baumgartner, C Büla, C Vaney, et al.
Pageof 5